166 related articles for article (PubMed ID: 32475902)
21. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of α-glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring.
Kurozumi A; Okada Y; Mori H; Arao T; Tanaka Y
J Diabetes Investig; 2013 Jul; 4(4):393-8. PubMed ID: 24843685
[TBL] [Abstract][Full Text] [Related]
23. Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Scott LJ
Drugs; 2010 Oct; 70(15):2051-72. PubMed ID: 20883057
[TBL] [Abstract][Full Text] [Related]
24. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
Nagai E; Katsuno T; Miyagawa J; Konishi K; Miuchi M; Ochi F; Kusunoki Y; Tokuda M; Murai K; Hamaguchi T; Namba M
Endocr J; 2011; 58(10):869-77. PubMed ID: 21869539
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase.
Kaku K; Mori M; Kanoo T; Katou M; Seino Y
Expert Opin Pharmacother; 2014 Oct; 15(15):2121-30. PubMed ID: 25190226
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study.
Inagaki N; Sano H; Seki Y; Kuroda S; Kaku K
J Diabetes Investig; 2016 Sep; 7(5):718-26. PubMed ID: 27181699
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
DeFronzo RA; Fleck PR; Wilson CA; Mekki Q;
Diabetes Care; 2008 Dec; 31(12):2315-7. PubMed ID: 18809631
[TBL] [Abstract][Full Text] [Related]
31. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin.
Kusunoki Y; Katsuno T; Myojin M; Miyakoshi K; Ikawa T; Matsuo T; Ochi F; Tokuda M; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
Endocr J; 2013; 60(4):431-9. PubMed ID: 23220949
[TBL] [Abstract][Full Text] [Related]
32. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
[TBL] [Abstract][Full Text] [Related]
33. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Triplitt C; Cersosimo E; DeFronzo RA
Vasc Health Risk Manag; 2010 Sep; 6():671-90. PubMed ID: 20859539
[TBL] [Abstract][Full Text] [Related]
34. [A compounding agent of alogliptin and pioglitazone].
Ueki K
Nihon Rinsho; 2011 May; 69(5):877-82. PubMed ID: 21595275
[TBL] [Abstract][Full Text] [Related]
35. Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
Matsuura K; Mori Y; Nakamura A; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2012 May; 14(5):423-9. PubMed ID: 22316114
[TBL] [Abstract][Full Text] [Related]
36. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
[TBL] [Abstract][Full Text] [Related]
37. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
[TBL] [Abstract][Full Text] [Related]
38. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
[TBL] [Abstract][Full Text] [Related]
39. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
[TBL] [Abstract][Full Text] [Related]
40. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.
Tai H; Wang MY; Zhao YP; Li LB; Dong QY; Liu XG; Kuang JS
Medicine (Baltimore); 2016 Aug; 95(33):e4541. PubMed ID: 27537577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
